How to Get Sermorelin Prescription: Priced in Visits, Not mg

The route exists because of a specific piece of regulatory history, and the detail matters because both of the usual summaries are wrong.

Sermorelin was an approved drug. EMD Serono marketed it as Geref under two applications: NDA 019863, a diagnostic presentation of 0.05 mg per ampoule, with submissions dating from 1991, and NDA 020443, a therapeutic presentation of 0.5 mg and 1 mg per vial, approved on 1997-09-26. Both applications now show a marketing status of Discontinued. The FDA product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons, and there is no current US label. DailyMed returns no labelling for it at all.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits a compounding pharmacy to use a bulk drug substance that is a component of an FDA-approved drug product, even where no monograph exists. Sermorelin acetate was a component of exactly such a product, so the compounding path did not close when Geref stopped being marketed.

The contrast makes it concrete. FDA maintains a Category 2 list of bulk substances that may present significant safety risks, and it names ibutamoren mesylate under both 503A and 503B, ipamorelin acetate under 503B, and GHRP-2, GHRP-6 and kisspeptin-10 as well. BPC-157, Melanotan II, Selank acetate, Semax, MOTS-c and epitalon were nominated and then withdrawn. Sermorelin appears in none of those sections, active or withdrawn, because it never needed nominating.

A prescription is the output of a clinical assessment, not a form to be completed, and the assessment has a predictable shape.

Expect a history and an examination first, then laboratory work. IGF-1 and growth hormone testing are the assays that come up in this area, because a growth hormone axis question is answered with measurements rather than symptoms. Expect the prescriber to be interested in why you are asking, and expect the answer to matter: the approved indications for this compound were paediatric growth hormone deficiency and pituitary diagnostics, not adult wellbeing.

Expect, too, that a prescriber may decline. That is a normal outcome of an assessment rather than a failure of the process, and a clinic that never declines is telling you something about its business model rather than about your results.

What you will not be asked for is a certificate, a lot number or a purity figure, because in this route the pharmacy carries the material question rather than you. That is the inverse of the research channel, where the buyer carries all of it and the only tool is a document. Our supplier criteria page covers what that document has to contain when the responsibility falls on you.

The pharmacy end of the route has boundaries worth knowing before you call one.

• It will fill against a valid prescription for an identified patient, prepared under section 503A conditions. That is the whole basis on which this compound remains available.
• It will not sell it to you without one. The gate is the prescriber, and no pharmacy can bypass that, which is why the sequence starts with a clinical appointment rather than a phone call to a pharmacy.
• It will not supply a research vial. A pharmacy preparation and a laboratory reagent are different products from different supply chains, and one does not substitute for the other in either direction.
• It will not tell you what your prescriber should write. Preparation follows the prescription, and this page publishes no dosing information of any kind: the approved dosing that ever existed was paediatric and given under specialist supervision.

Outsourcing facilities registered under 503B operate on a different basis from 503A pharmacies, with different rules about bulk substances. For an individual with a prescription, the 503A pharmacy is the relevant one.

This is where most pages on this topic invent a number, and where this one will not.

The prescription route has three cost components: the consultation, the laboratory panel and the pharmacy fill. Each varies by clinician, by state and by pharmacy, and none of them is published in a form that can be sourced the way a product price can. A monthly figure quoted with confidence on a page like this one is an estimate wearing the clothes of a fact.

What can be stated is the structure of the difference. Compare the two columns rather than the two prices.

Reading down the first column and then the second is more useful than any dollar comparison, because the rows are not alternatives to each other. The cheaper option is cheaper because it includes less, and the specific things it excludes are the rows with no numbers in them.

This site links a research listing and the arithmetic on it is good: $99.99 list, $72.00 site price, $36.00 with the code, which is $10.00, $7.20 and $3.60 per labelled milligram, or $8.84, $6.37 and $3.18 against the 11.31 mg that lot 38-01260229 assayed. Quantity tiers take 3 %, 5 % or 10 % off list separately and land no better than $9.00 per labelled milligram, so the code is the only lever that moves the rate.

The certificate behind those figures reports 99.79 % purity by HPLC-UV-MS across 4 detected peaks, analysed at MZ Biolabs in Tucson, Arizona on 2026-02-07 and signed on 2026-02-13. It carries no endotoxin test and no sterility test, and that scope belongs to the lot rather than to the vendor or the product.

If the prescription route is what you actually want, none of the above is a substitute for it. A vial is powder and a document. It contains no assessment of whether the purchase makes sense for you, no monitoring and nobody to call afterwards, and it is sold as laboratory material rather than for human use. A page that presents the two side by side as if the cheaper one wins is comparing a product with a service and hiding the difference in a price. Our routes page ranks both by what they ask of you rather than by cost.

A lawful route is not an evidence base, and this page would be worth less if it stopped before saying so.

PubMed returns 332 records mentioning this compound, 3 with it in the title and 29 tagged as clinical trials. Searched alongside anti-aging the count is zero. ClinicalTrials.gov registers no studies naming it, which means every trial identifier you see attached to this compound elsewhere belongs to something else, usually a GHRH, tesamorelin or octreotide study.

The three papers carrying the term in the title are a 2006 review in Clinical Interventions in Aging on adult-onset growth hormone insufficiency (PMID 18046908), a 1999 BioDrugs review of use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (PMID 18031173), and a 2021 paper in Annals of Translational Medicine on recurrent glioma (PMID 33842627), which answers no question a buyer has.

So the honest summary is two sentences that have to travel together. A prescription route genuinely exists for this compound, which is not true of most things sold alongside it. And the adult uses the clinic market advertises are the part of the picture the literature does not cover, which no prescription changes.